As per the terms of the agreement, Arno will pay certain research, clinical and regulatory milestone payments as well as royalties on net sales of licensed products to Invivis.
Arno will also receive certain clinical development support services from Invivis pursuant to a separate agreement.
Arno president and CEO Glenn Mattes said Onapristone appears to have a unique ability to block the activated bio-marker and tumor growth.
"We have prepared a detailed development program for this compound and look forward to evaluating it in future clinical trials," Mattes added.